| Analysis | Metabolite Name | Measured Value | Units | Sample source | MECFS_STATUS | SEX |
|---|---|---|---|---|---|---|
| Reversed phase POSITIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 244026 | Peak area | CSF | MECFS | F |
| Reversed phase POSITIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 280217 | Peak area | CSF | MECFS | F |
| Reversed phase POSITIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 306383 | Peak area | CSF | MECFS | M |
| Reversed phase POSITIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 323371 | Peak area | CSF | Healthy volunteer | F |
| Reversed phase POSITIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 333438 | Peak area | CSF | MECFS | F |
| Reversed phase POSITIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 351373 | Peak area | CSF | Healthy volunteer | F |
| Reversed phase POSITIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 384575 | Peak area | CSF | Healthy volunteer | F |
| Reversed phase POSITIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 390898 | Peak area | CSF | MECFS | F |
| Reversed phase POSITIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 459719 | Peak area | CSF | Healthy volunteer | M |
| Reversed phase POSITIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 469305 | Peak area | CSF | MECFS | F |
| Reversed phase POSITIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 494575 | Peak area | CSF | MECFS | M |
| Reversed phase POSITIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 504163 | Peak area | CSF | MECFS | F |
| Reversed phase POSITIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 517359 | Peak area | CSF | MECFS | M |
| Reversed phase POSITIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 524253 | Peak area | CSF | Healthy volunteer | F |
| Reversed phase POSITIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 531139 | Peak area | CSF | Healthy volunteer | M |
| Reversed phase POSITIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 556868 | Peak area | CSF | Healthy volunteer | M |
| Reversed phase POSITIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 557087 | Peak area | CSF | MECFS | F |
| Reversed phase POSITIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 562914 | Peak area | CSF | Healthy volunteer | M |
| Reversed phase POSITIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 573756 | Peak area | CSF | Healthy volunteer | F |
| Reversed phase POSITIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 596440 | Peak area | CSF | Healthy volunteer | F |
| Reversed phase POSITIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 615368 | Peak area | CSF | MECFS | F |
| Reversed phase POSITIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 630000 | Peak area | CSF | MECFS | M |
| Reversed phase POSITIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 649625 | Peak area | CSF | MECFS | F |
| Reversed phase POSITIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 652391 | Peak area | CSF | Healthy volunteer | F |
| Reversed phase POSITIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 660647 | Peak area | CSF | Healthy volunteer | M |
| Reversed phase POSITIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 689716 | Peak area | CSF | Healthy volunteer | F |
| Reversed phase POSITIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 701597 | Peak area | CSF | Healthy volunteer | F |
| Reversed phase POSITIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 716904 | Peak area | CSF | MECFS | M |
| Reversed phase POSITIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 757709 | Peak area | CSF | Healthy volunteer | M |
| Reversed phase POSITIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 764346 | Peak area | CSF | Healthy volunteer | M |
| Reversed phase POSITIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 795694 | Peak area | CSF | Healthy volunteer | M |
| Reversed phase POSITIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 828107 | Peak area | CSF | MECFS | M |
| Reversed phase POSITIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 878494 | Peak area | CSF | Healthy volunteer | M |
| Reversed phase POSITIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 998921 | Peak area | CSF | Healthy volunteer | M |
| Reversed phase POSITIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 1087146 | Peak area | CSF | MECFS | F |
| Reversed phase POSITIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 1232264 | Peak area | CSF | MECFS | M |
| Reversed phase POSITIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 1646774 | Peak area | CSF | Healthy volunteer | F |
| Reversed phase POSITIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | Peak area | CSF | Healthy volunteer | F |
- UCSD Metabolomics Workbench, a resource sponsored by the Common Fund of the National Institutes of Health
|